Synedgen   Report issue

For profit Phase 4
Founded: Claremont CA United States (2009)

Organization Overview

First Clinical Trial
2021
NCT04601532
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Synedgen, Inc | Synedgen, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

silver sulfadiazine (silvadene) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 1